RenovoRx Case Study Shows 52% Tumor Metabolic Reduction Using TAMP in Pancreatic Cancer
RNXT•A peer-reviewed case study describes coil plus glue embolization of a pancreaticoduodenal branch to enable RenovoCath-mediated TAMP delivery of intra-arterial gemcitabine in an 82-year-old patient with unresectable locally advanced pancreatic cancer. After eight treatments, CT scans showed stable disease and PET-CT revealed a 52% reduction in tumor metabolic activity.
1. Case Study Details
RenovoRx reported a peer-reviewed case study in Radiology Case Reports detailing an 82-year-old patient with unresectable locally advanced pancreatic cancer who received eight intra-arterial gemcitabine treatments via its RenovoCath-enabled TAMP platform. Investigators performed coil plus glue embolization of a pancreaticoduodenal side branch to isolate arterial flow and deliver chemotherapy directly to the tumor in a single procedural setting.
2. Treatment Outcomes
Follow-up CT scans at four months showed stable disease, while PET-CT imaging demonstrated a 52% reduction in fluorodeoxyglucose activity at the treatment site. The patient completed all eight TAMP procedures without complications, highlighting the safety and potential efficacy of localized drug delivery.
3. Platform Implications and Next Steps
The case study underscores the procedural flexibility of TAMP therapy to overcome anatomical challenges and optimize localized drug delivery with RenovoCath, potentially enhancing therapeutic benefits for difficult-to-treat cancers. RenovoRx anticipates full enrollment in its Phase III TIGeR-PaC trial by June 2026, with final data expected in mid to late 2027 to further validate this targeted approach.
